ASP 3652

Drug Profile

ASP 3652

Alternative Names: ASP-3652

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class
  • Mechanism of Action Afferent neuron inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Interstitial cystitis; Prostatitis

Most Recent Events

  • 31 Oct 2014 Discontinued - Phase-I for Interstitial cystitis in Japan (PO)
  • 31 Oct 2014 Discontinued - Phase-II for Interstitial cystitis in Belgium, Czech Republic, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russia and Spain (PO)
  • 31 Mar 2014 Astellas Pharma completes the phase II AMARANTH trial in Interstitial cystitis in Belgium, Czech Republic, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Spain and Russia (NCT01613586)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top